Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharmaceutical Tech Co. Ltd. have divulged new polycyclic lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of small-cell lung cancer (SCLC).
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new fused tetracyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1, MEKKK1) inhibitors reported to be useful for the treatment of cancer, diabetes, inflammation, infections, neurodegeneration and autoimmune, cardiovascular and reproductive disorders.
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis.
Adlai Nortye Ltd. has described mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer, immunological and inflammatory disorders.
Hangzhou Apeloa Medicine Research Institute Co. Ltd. and Apeloa Pharmaceutical Co. Ltd. have disclosed fibroblast growth factor receptor 4 (FGFR-4) inhibitors reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to epidermal growth factor receptor (EGFR)-binding moiety through linker reported to be useful for the treatment of cancer.
RSS